Next-Generation Phage Therapy Combining CRISPR and Near-Infrared Imaging: New Hope for MDR and XDR Bacteria
Threat of Multidrug-Resistant Bacteria and the Resurgence of Phage Therapy
The recent surge in MDR and XDR bacterial infections has exposed the limitations of conventional antibiotics. In this context, efforts to reintroduce natural bacteriophages into modern medicine are gaining momentum.
Tailored Design of Phage Host Range and Lytic Activity Using CRISPR
The research team employed CRISPR-based genome editing to precisely modulate phage infection specificity and lytic efficiency. This enabled the creation of phages that directly target specific resistance genes, achieving bacterial clearance more than tenfold faster than unmodified phages.
Real-Time Tracking of Therapy Progress with Near-Infrared Bioimaging
Phages were labeled with a near-infrared fluorescent tag, allowing visualization of their distribution and infection dynamics in vivo. Consequently, therapeutic efficacy could be monitored in real time, facilitating optimization of dose and administration timing.
Future Outlook: Will Precision Phage Therapy Become Routine?
The goal is to commercialize a customizable antimicrobial platform that integrates CRISPR-engineered phages with imaging technology. The advent of “smart phages” tailored to individual patients’ microbiomes may soon become a standard prescription.
The rapid rise of multidrug-resistant and extensively drug-resistant bacterial infections has renewed interest in bacteriophages as adaptable, targeted antimicrobials. Recent advances in phage engineering, including CRISPR-based approaches, now make it possible to refine host range, strengthen lytic performance, and deliver genetic payloads that target clinically important resistance determinants such as
Multidrug-resistant bacterial infections represent a genuine crisis that is difficult to treat with existing antibiotics. If this novel phage therapy becomes widely applied, we will all be safer from infection risks.